Edonerpic maleate - CAS:519187-97-4

您当前的位置：

Edonerpic maleate (Synonyms:T-817 maleate; T-817MA)

目录号 : KM14380 CAS No. : 519187-97-4 纯度 : 98%

Data Sheet 产品使用指南

Edonerpic maleate 是一种新的神经营养剂，其可以抑制淀粉样蛋白 β 肽 (Aβ)。

规格	价格	是否有货
1mg		In-stock
5mg		In-stock
10mg		In-stock
50mg		In-stock
100mg		In-stock
200mg	询价	In-stock
500mg	询价	In-stock

查看所有商品（2）

加入购物车大包装询价

Other Forms of Rapamycin:

Ginkgolide J In-stock
Ginkgolide K In-stock
THK-5470 In-stock
NH-3 In-stock
Velufenacin In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

Edonerpic maleate is a novel neurotrophic agent which can inhibit amyloid-β peptides (Aβ).

体外研究

Edonerpic maleate (T-817MA) treatment preserves the cortical neurons in the presence of Aβ(1-42). Twenty-four hours of pretreatment, followed by the continuous presence of Edonerpic maleate, prevents oxidative stress-induced neuronal death at 0.1 and 1 μM. Edonerpic maleate almost completely prevents GSH reduction at 0.1 and 1 μM. Hippocampal slices with 1 μM Edonerpic maleate treatment generate more and much longer neurites than control slices. Edonerpic maleate significantly increases the neurite length at 0.1 and 1 μM.

体内研究

The post hoc test indicates that the mean density of PSA-positive cells is significantly larger in the vehicle and Aβ infusion+high-dose Edonerpic maleate (T-817MA) groups than that in the Aβ infusion control group (P<0.01). The results indicate that the vehicle and Aβ infusion+high-dose Edonerpic maleate groups display efficient learning in the place learning task (PLT), while these two groups also display vigorous neurogenesis. Treatment with Edonerpic maleate and donepezil does not increase the mean density of normal granule cells; there are no significant differences in the mean granule cell density among the Aβ infusion control, Aβ infusion+high-dose Edonerpic maleate, Aβ infusion+low-dose Edonerpic maleate and Aβ infusion+donepezil groups.

分子式

C₂₀H₂₅NO₆S

分子量

407.48

CAS号

519187-97-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 100 mg/mL (245.41 mM; Need ultrasonic)

H₂O : 100 mg/mL (245.41 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4541 mL	12.2705 mL	24.5411 mL
5 mM	0.4908 mL	2.4541 mL	4.9082 mL
10 mM	0.2454 mL	1.2271 mL	2.4541 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： PBS
Solubility: 140 mg/mL (343.58 mM); Clear solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (6.14 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.14 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.14 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.14 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

临床试验

纯度： 98%

Data Sheet

产品使用指南

摩尔计算器
稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量

浓度

体积

分子量*

重置计算

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度

体积

浓度

体积

重置计算

Other Forms of Rapamycin:

KKL 顾客使用本产品发表的 0 篇科研文献

The molarity calculator equation

The dilution calculator equation